Evaluation of Hemoglobin and Eosinophil Count in Patients Receiving Thrombolytic Treatment.

Autor:	Yazıcı R; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Güner M; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Basa Kalafat AF; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Tapkan RB; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Kaya H; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Yeniyurt B; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Fettahoğlu S; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Kalafat UM; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Bala ED; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR., Doğan S; Emergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jul 15; Vol. 16 (7), pp. e64575. Date of Electronic Publication: 2024 Jul 15 (Print Publication: 2024).
DOI:	10.7759/cureus.64575
Abstrakt:	Background and aim Stroke ranks among the primary contributors to disability and mortality on a global scale. Recent advances in ischemic stroke pathophysiology emphasize the significant role of the immune system in both stroke-related damage and neuroprotection. This article investigates the relationship between hemoglobin level and white blood cell count. Materials and methods From January 1, 2019, to April 1, 2022, all patients aged 18 years and over who were diagnosed with acute ischemic stroke in the emergency department of Kanuni Sultan Süleyman Training and Research Hospital and treated with intravenous recombinant tissue plasminogen activator (r-tPA) within 4.5 hours of stroke onset were included in this cross-sectional retrospective study. Gender, age, onset of symptoms, complaints, National Institutes of Health Stroke Scale (NIHSS) score, stroke-affected area, as well as leukocyte, neutrophil, platelet, eosinophil, lymphocyte, and hemoglobin levels were recorded and compared between mortality and survivor groups. Results A total of 61 people, including 33 men and 28 women, were included in the study. Four patients died during follow-ups. The mean duration of symptoms upon admission was 86.23 ± 56.37 minutes. The mean NIHSS score of patients was found to be 9.16 ± 3.88 (minimum: 4, maximum: 18). There was a statistically significant positive correlation between age and symptom duration (p < 0.002, r: 0.391). A statistically significant negative correlation was found between eosinophil count and NIHSS score (p < 0.012, r: -0.321) and between eosinophil count and symptom duration (p < 0.042, r: -0.261). There was a negative correlation between hemoglobin levels and mortality (p < 0.013, r: -0.318). A statistically significant negative correlation was observed between the eosinophil-to-neutrophil ratio (ENR) and NIHSS score (p < 0.017, r: -0.305) as well as between ENR and symptom duration (p < 0.034, r: -0.271). Hemoglobin is a significant predictor of mortality in the logistic regression model (p < 0.05, CI: 0.253-0.942). For each one-unit increase in hemoglobin, the odds of mortality decrease by a factor of 0.488. Conclusion Certain blood cell types (neutrophils, eosinophils, and lymphocytes) play an active role in determining stroke prognosis. A detailed explanation of the role of leukocyte types lays the foundation for "immunomodulation," which could be a promising novel treatment modality for future stroke patients. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Medical Research Scientific and Ethical Evaluation Board of Kanuni Sultan Suleyman Training and Research Hospital issued approval KAEK/2022.05.113. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Yazıcı et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu